BioLineRx sells APHEXDA royalty rights to Soleus Capital for $5.6 million
The deal funds BioLineRx's GLIX1 glioblastoma program and triggers a partial repayment of its loan with Kreos Capital.
BioLineRx Ltd. said on November 18, 2026 that it had agreed to sell a portion of its future royalty rights on APHEXDA (motixafortide) to Soleus Capital Management, L.P. and its affiliates. The Company entered into a Purchase and Sale Agreement on November 17, 2026 with SCOF Motixafortide Holdings, Inc., a Delaware corporation and an affiliate of Soleus Capital Management, L.P., agreeing to sell a portion of its right to future APHEXDA royalty payments under its license agreement with Ayrmid Pharma Ltd., dated November 20, 2024, as amended.1 In exchange, the purchaser will pay BioLineRx a one-time purchase price of $5.6 million at closing, minus the purchaser's documented reasonable transaction expenses, which are capped at $100,000.1
Under the agreement, BioLineRx will transfer 80% of the royalty payments it is owed under the Ayrmid license for sales occurring on or after the closing date, along with related rights such as payments for underpayments, late payments, or royalties from any replacement license following termination of the Ayrmid agreement.1 BioLineRx will keep the remaining 20% of the royalty stream, which equates to a 3.6% royalty on net sales, tied to its 18% total royalty rate under the Ayrmid license; that retained share corresponds to payments owed to Biokine Therapeutics Ltd., the original licensor of motixafortide to BioLineRx.1 BioLineRx will retain all rights to any future milestone payments under the Ayrmid license.1
Kreos Capital VII Aggregator SCSp, an affiliate of BlackRock and the lender under BioLineRx's 2022 loan agreement, consented to the transaction and will receive a $3.0 million partial prepayment at closing, with the remaining roughly $2.0 million balance repaid under a new schedule; the loan's $4.0 million minimum cash covenant will be eliminated.1 Chardan Capital Markets, LLC advised BioLineRx on the deal and will earn an advisory fee of about $0.4 million at closing.1 The transaction is expected to close on or about November 30, 2026, subject to customary closing conditions.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.